ArticleCell biochemistry and biophysics2026
Fatty Acid-enriched Euphorbia neriifolia Alleviates the NPIP-induced Lung Cancer Via Modulating Oxidative Stress and Apoptosis in Swiss Albino Mice.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study aims to determine: (i) the effect of isolated compounds (ICs) from E. neriifolia leaf via TLC and HPTLC on the lung cancer target protein through molecular docking; (ii) the cytotoxicity (MTT; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and proapoptotic effect (DAPI; 4’-6-diamidino-2-phenylindole) of isolated linoleic acid (LA) in A549 cells; (iii) the in vivo anticancer potential of ENLE extract and LA against N-nitrosopiperidine (NPIP)-induced lung cancer in Swiss albino mice. Results revealed that LA was determined to be the better one among the studied ICs. This is due to its binding energy (-4.8 kcal/m and − 4.3 kcal/m), pharmacokinetic properties, and drug-likeliness. The LA decreased cell proliferation and viability above 400 µM after 24 and 48 h treatment. Apoptotic changes were revealed in treated adenocarcinoma (A549) cells with an IC50 dose of LA. The in-vivo analysis in Swiss albino mice (5–6 week old; 28–30 g) revealed that the administration of NPIP resulted in a reduction in body weight with a rise in serum levels of tumor markers (LDH, ADA, and 5’-ND), TP, and LPO. Metastasis markers (hexose, hexosamine, sialic acid, and uronic acid) with a concomitant reduction in the levels of enzymatic (SOD, CAT, and GPx), and non-enzymatic antioxidants (Vitamin E and Vitamin C) were also observed in response to NPIP administration. Moreover, high doses of ENLE, gefitinib (positive standard drug), and LA treatment significantly restored biochemical levels. Histological analyses showed restoration of normal architecture in the ENLE- and LA-treated groups. Immunohistology analyses revealed decreased p53 overexpression and normal CK7 levels compared with the NPIP group, indicating their protective effect. A high dose of ENLE after oral administration shows a remarkable decrease in tail length. The % tail DNA at a high dose of ENLE was determined to be 15.53 ± 0.11. Thus, the current study findings provide indications regarding the therapeutic potential of ENLE and LA against NPIP-induced lung cancer.
Indexed as
Identifiers
41735757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.